Since October 7, 2023, our strongest ally in the Middle East, Israel, has withstood various terrorist attacks from Iran and its proxies, including Hamas, Palestinian Islamic Jihad, Hezbollah, and others. Instead of standing by Jerusalem, the Biden-Harris...
News
Latest News
Rubio: “The Court is Right: Algorithms Should Not Enjoy Section 230 Protections”
TikTok was recently sued after a 10-year-old girl died from taking part in a viral challenge that dared users on the app to choke themselves until they passed out. Courts have historically protected social media companies over user-generated content due to...
Rubio, Moolenaar Demand Communist China-linked Battery Company Be Blacklisted
Contemporary Amperex Technology Limited (CATL) is an electric vehicle battery company with deep ties to the Chinese Communist Party and its armed wing, the People’s Liberation Army (PLA). Reliance on, and use of, CATL batteries threatens U.S. national security as it...
Rubio: Communist China Making a Mockery of Biden-Harris Administration
Despite the serious threats the Chinese Communist Party poses to the United States and our allies, National Security Advisor Jake Sullivan is in the midst of a three day visit with Chinese Foreign Minister Wang Yi in another embarrassing attempt to “lower tensions”...
Rubio Calls on John Deere to Prioritize American Workers
John Deere, the world’s largest tractor manufacturer, is a staple of American business and a crucial supplier for the hard working Americans who grow our food. Recently, after receiving public backlash, John Deere ended several ridiculous Diversity, Equity, and...
Rubio Y Colegas: Esto No Se Trata de Ideología Política, Se Trata de Defender la Voluntad del Pueblo Venezolano
Hace casi un mes, el pueblo venezolano votó por Edmundo González Urrutia como su presidente electo. Ayer, el Tribunal Supremo de Justicia del narco-régimen de Maduro optó por legitimar el fraude electoral de la dictadura. Los senadores estadounidenses Marco Rubio...
Rubio, Grassley Call on HHS IG to Examine Payments to Chinese-Linked Companies
Washington, D.C. — Today, U.S. Senators Marco Rubio (R-FL) and Chuck Grassley (R-IA) sent a letter to Department of Health and Human Services (HHS) Acting Inspector General (IG) Joanne M. Chiedi requesting oversight on potential payments made to U.S. entities with partnerships to genomics companies affiliated with the Chinese government, including WuXi and BGI. Both WuXi and BGI have publicly touted their partnerships with the Chinese telecom company Huawei, a state-directed actor used by the Chinese government and Communist Party to undermine U.S. companies and steal intellectual property and trade secrets.
Rubio and Grassley are specifically asking the HHS IG for the following:
- A review of Centers for Medicare and Medicaid Services (CMS) payments to determine whether it has made payments for Americans’ genetic testing to U.S. entities with partnerships to BGI, WuXi and any other company with ties to the Chinese government;
- To determine whether CMS considers national security risks when determining whether payments are permissible to providers with partnerships with these Chinese-affiliated companies; and,
- That the IG make recommendations to CMS and to Congress on ways to mitigate national security risks related to Americans’ genomic data with respect to CMS payments.
The full text of the letter is below.
Dear Acting Inspector General Chiedi:
According to a February 2019 report released by the U.S. Department of Health and Human Services Office of the Inspector General (OIG), the Federal Bureau of Investigation (FBI) has identified national security risks related to sharing genomic data, and recognizes China as a country as a primary source of those risks. The report raises concerns that the National Institutes of Health (NIH) gave access to U.S. genomic data to for-profit companies from China, including WuXi Nextcode Genomics (WuXi) and Shenzhen BGI Technology Company (BGI), “even though the FBI has identified those companies as having ties to the Chinese Government.” We agree with your office’s recommendations for the NIH to work with national security experts to assess the potential consequences of providing foreign entities access to Americans’ genomic information. We also support your efforts to bring this issue to the NIH’s attention and its recommendation that NIH work to mitigate these risks.
We are equally concerned that CMS may be providing payments for genetic testing or analysis to U.S. entities that have domestic partnerships with WuXi, BGI, and other genomics companies with ties to the Chinese government. In 2016, WuXi was the first genetic sequencing facility in China to gain CLIA (Clinical Laboratory Improvement Amendments) certification from CMS. It has since gained a foothold in the U.S. Similarly, BGI has publicly announced partnerships with leading American health care systems, including those that accept Medicare and Medicaid patients. In 2013, BGI acquired Complete Genomics, a U.S. company which later became part of MGI Tech (MGI), a BGI subsidiary. In March 2019, MGI announced plans to expand into the U.S. market by the end of 2019, making it all the more necessary for the OIG to determine whether CMS has the proper security protocols in place to protect Americans’ genetic information.
Both BGI and WuXi also have publicly touted their partnerships with Huawei to expand genomic analytics. As you know, Huawei is a State-directed Chinese telecommunications company that, according to the heads of six U.S. intelligence agencies including the CIA, FBI, NSA, and the Director of National Intelligence, possesses the capabilities to “maliciously modify or steal information” and “to conduct undetected espionage.” This is the same company that the U.S. recently charged with conspiring to defraud our nation and stealing trade secrets, among other crimes. WuXi and BGI’s U.S.-based partnerships give them unique access to genomic data, including Americans’ genomic data. Therefore, it is particularly alarming that these two companies have partnered with Huawei.
As of March 2019, the Congressional Budget Office estimates that the federal government’s gross spending on Medicare in 2018 was $712 billion, while federal Medicaid expenditures were $389 billion, not including the states’ Medicaid spending. Together, these two programs totaled more than $1.1 trillion in federal outlays in 2018 – far more than federal funding to the NIH. Taxpayers cover the costs of CMS payments. Accordingly, they have every right to know if their money has gone to entities connected to the Chinese government.
We therefore request that the OIG, in coordination with relevant Intelligence Community agencies, review CMS payments to determine whether it has made payments for genetic testing to U.S. entities with partnerships to BGI, WuXi and any other company with ties to the Chinese government. We also request that the OIG determine whether the CMS considers national security risks when determining whether payments are permissible to providers with partnerships with these Chinese-affiliated companies. Finally, we ask that the OIG make recommendations to CMS and to Congress on ways to mitigate national security risks related to Americans’ genomic data with respect to CMS payments.
Sincerely,